Alefacept
- Atc Codes:L04AA15
- CAS Codes:222535-22-0
- PHARMGKB ID:222535-22-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
Canada: Amevive; USA: Amevive.
Drug combinations
Chemistry
Alefacept: C~3264~H~5002~N~840~O~988~S~20~. Mw: 36235.01-36837.01 (1) 1-92-LFA-3 (Antigen)(human) fusion protein with immunoglobulin G~1~ (human hinge-CH~2~-CH~3~ γ~1~-chain), dimer; (2) 1-92-Antigen LFA 3 (human) fusion protein with human immunoglobulin G~1~ (hinge-CH~2~-CH~3~ γ~1~-chain), dimer. CAS-222535-22-0 (2000).
Pharmacologic Category
Skin and Mucous Membrane Agents; Antipsoriatics. Immunosuppressive Agents. Monoclonal Antibody. (ATC-Code: L04AA15).
Mechanism of action
Binds to CD2, a receptor on the surface of lymphocytes, inhibiting their interaction with leukocyte functional antigen 3 (LFA-3). Interaction between CD2 and LFA-3 is important for the activation of T lymphocytes in psoriasis.
Therapeutic use
Treatment of chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Pregnancy and lactiation implications
Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to alefacept or any component of the formulation. History of severe malignancy. HIV infection or other clinically-important infections.
Warnings and precautions
Hepatic injury (significant transaminase elevations, rare cases of hepatitis, fatty liver, decompensation of cirrhosis, and acute hepatic failure have occurred). Hypersensitivity reactions. Immune suppression (may increase risk of infection and may reactivate latent infection). Acute infusion reactions may occur. Lymphopenia (induces a decline in circulating T-lymphocytes (CD4^+^ and CD8^+^)). May increase risk of malignancies. Live vaccines should not be given concurrently.